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iNKT cells are CD1d-restricted T cells that are rapidly acti-
vated in response to antigen and play a key role in promot-
ing adaptive anti-tumor immunity. Surprisingly, we found
that mice bearing 4T1 breast cancer CD8+ T cells inhibited
spontaneous metastases in the absence of iNKT cells, sug-
gesting that iNKT cells were suppressing the onset of CD8
+ anti-tumor T cell responses. iNKT-deficient (iNKT-/-)
mice also showed a markedly improved response to treat-
ment with local radiotherapy (RT) and anti-CTLA-4 anti-
body (Pilones et al., Clin Cancer Res 2009). Moreover,
administration of iNKT cell activator b-galactosyl-ceramide
to wild type (WT) mice did not induce anti-tumor
responses to 4T1. To understand the mechanisms of this
unexpected iNKT immunosuppression, we analyzed den-
dritic cells (DC) in 4T1 tumor-bearing mice for differences
that could explain the decreased priming of anti-tumor
T cells in WT compared to iNKT-/- mice. Mice were
inoculated subcutaneously with 4T1 tumor cells on day 0.
Tumor and lymph nodes (LN) were analyzed for DC
numbers and maturation. Mice were treated with RT+anti-
CTLA-4 antibody, as previously described. To block CD1d
in vivo, mice were given 3 doses of anti-CD1d mAb (Clone
20H2) on days 3, 7 and 11 post tumor inoculation. Mice
were followed for tumor growth and survival, and long-
term survivors were given a second tumor challenge to
assess anti-tumor memory responses. In vitro cytotoxicity
assays were used to determine if DC loaded with 4T1
tumor lysate were killed by iNKT cells. DC numbers were
similar in healthy WT and iNKT-/- mice, while 4T1
tumor-bearing WT mice showed a significantly lower
number of DC compared to iNKT-/- mice in the tumors
(p=0.004) and draining LN (p<0.05) but not in non-drain-
ing LNs (p=0.782). Intratumoral DCs from iNKT-/- mice
further showed increased expression of maturation
markers compared to DC from WT mice. Blockade of
CD1d restored DC numbers in tumor and draining LN of
WT mice and markedly improved the therapeutic response
to RT+anti-CTLA-4, with some mice showing complete
tumor rejection and long-term protective memory
responses. DCs loaded with 4T1 tumor lysates were killed
by iNKT cells in vitro and killing was CD1d-dependent.
4T1 cells, which express minimal surface levels of CD1d,
were resistant to NKT cell-mediated killing. Here we
describe a novel mechanism of immune escape by tumors,
namely the elimination by iNKT cells of DC cross-present-
ing tumor antigens in the tumor and draining LN. Data
suggest that CD1d blockade may help overcome iNKT-
mediated suppression and improve response of some
tumors to immunotherapy.
Authors’ details
1Pathology, NYU School of Medicine, New York, NY, USA. 2Radiation
Oncology, NYU School of Medicine, New York, NY, USA.
Published: 7 November 2013
doi:10.1186/2051-1426-1-S1-P117
Cite this article as: Pilones et al.: Dendritic cells cross-presenting tumor-
derived antigens are eliminated by invariant natural killer T (iNKT) cells,
impairing development of anti-tumor immunity to a mouse carcinoma.
Journal for ImmunoTherapy of Cancer 2013 1(Suppl 1):P117.
1Pathology, NYU School of Medicine, New York, NY, USA
Full list of author information is available at the end of the article
Pilones et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P117
http://www.immunotherapyofcancer.org/content/1/S1/P117
© 2013 Pilones et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
